<DOC>
	<DOCNO>NCT01600716</DOCNO>
	<brief_summary>This study evaluate safety efficacy OnabotulinumtoxinA ( BOTOXÂ® ) treatment urinary incontinence due NDO non-catheterizing patient MS .</brief_summary>
	<brief_title>Safety Efficacy Study OnabotulinumtoxinA Treatment Urinary Incontinence Due Neurogenic Detrusor Overactivity ( NDO ) Non-Catheterizing Patients With Multiple Sclerosis ( MS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Bladder , Neurogenic</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>At least 3 episode urinary incontinence 3day period History Multiple Sclerosis ( MS ) Urinary incontinence adequately control anticholinergic medication Current use intermittent catheter indwell catheter manage urinary incontinence Previous current botulinum toxin therapy serotype urological condition Previous current botulinum toxin therapy serotype nonurological condition within last 12 week Diagnosis myasthenia gravis , EatonLambert Syndrome , Amyotrophic Lateral Sclerosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>